SOUTH SAN FRANCISCO, Calif., June 2 /PRNewswire-FirstCall/ -- Titan Pharmaceuticals, Inc. today announced that its common stock has commenced trading on the OTC Bulletin Board under the symbol TTNP:OB following approval of the listing by the Financial Industry Regulatory Authority (FINRA).
The Company also announced that last week the United States Patent and Trademark Office (USPTO) posted a patent issue notification containing a projected issuance date of June 15, 2010 for Titan's United States patent application directed to the use of Probuphine® for the treatment of opiate addiction.
About Titan Pharmaceuticals
For information concerning Titan Pharmaceuticals, Inc., please visit the Company's website at www.titanpharm.com.
The press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to the Company's development program and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in development, testing, regulatory approval, production and marketing of the Company's drug candidates, adverse side effects or inadequate therapeutic efficacy of the Company's drug candidates that could slow or prevent product development or commercialization, the uncertainty of patent protection for the Company's intellectual property or trade secrets, and the Company's ability to obtain additional financing. Such statements are based on management's current expectations, but actual results may differ materially due to various factors, including those risks and uncertainties mentioned or referred to in this press release.
Titan Pharmaceuticals, Inc.
Sunil Bhonsle, 650-244-4990
SOURCE Titan Pharmaceuticals, Inc.